Inhibition of casein kinase 2 prevents growth of human osteosarcoma

• Published in: Oncology reports Vol. 37; no. 2; pp. 1141 - 1147
• Main Authors: Takahashi, Kengo, Setoguchi, Takao, Tsuru, Arisa, Saitoh, Yoshinobu, Nagano, Satoshi, Ishidou, Yasuhiro, Maeda, Shingo, Furukawa, Tatsuhiko, Komiya, Setsuro
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01-02-2017; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Arsenic; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - enzymology; Bone Neoplasms - pathology; Breast cancer; Cancer therapies; Care and treatment; casein kinase 2; Casein Kinase II - antagonists & inhibitors; Casein Kinase II - genetics; Casein Kinase II - metabolism; Cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Cell Survival - genetics; Clinical trials; Development and progression; Drug dosages; Enzymes; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Genetic aspects; Health aspects; Humans; Kinases; Laboratory animals; Lung cancer; Medical prognosis; Medical research; Metastasis; Mice; Naphthyridines - pharmacology; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - enzymology; Osteosarcoma - pathology; Phosphotransferases; Proteins; Regulation; RNA, Small Interfering - genetics; Sarcoma; Stem cells; Studies; Tumors; Xenograft Model Antitumor Assays; United States > US; Japan
• ISSN: 1021-335X; 1791-2431
• DOI: 10.3892/or.2016.5310

High-dose chemotherapy and surgical treatment have improved the prognosis of osteosarcoma. However, more than 20% of patients with osteosarcoma still have a poor prognosis. We investigated the expression and function of casein kinase 2 (CK2) in osteosarcoma growth. We then examined the effects of CX-4945, a CK2 inhibitor, on osteosarcoma growth in vitro and in vivo to apply our findings to the clinical setting. We examined the expression of CK2α and CK2β by western blot analysis, and performed WST-1 assays using CK2α and CK2β siRNA or CX-4945. Flow cytometry and western blot analyses were performed to evaluate apoptotic cell death. Xenograft models were used to examine the effect of CX-4945 in vivo. Western blot analysis revealed upregulation of CK2α and CK2β in human osteosarcoma cell lines compared with human osteoblast cells or mesenchymal stem cells. WST assay showed that knockdown of CK2α or CK2β by siRNA inhibited the proliferation of human osteosarcoma cells. Treatment with 3 µM of CX-4945 inhibited osteosarcoma cell proliferation; however, the same concentration of CX-4945 did not affect the proliferation of human mesenchymal stem cells. Additionally, treatment with CX-4945 inhibited the proliferation of human osteosarcoma cells in a dose-dependent manner. Western blot and flow cytometry analyses showed that treatment with CX-4945 promoted apoptotic death of osteosarcoma cells. The xenograft model showed that treatment with CX-4945 significantly prevented osteosarcoma growth in vivo compared with control vehicle treatment. Our findings indicate that CK2 may be an attractive therapeutic target for treating osteosarcoma.